A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment

Jinhyun Kim, Heejung Ryu, Dae Hyun Yoo, Sung Hwan Park, Gwan Gyu Song, Won Park, Chul Soo Cho, Yeong Wook Song

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Currently, infliximab is given for disease control for active rheumatoid arthritis (RA) patients despite methotrexate treatment. However, the efficacy and safety of infliximab in Korean patients has not been assessed appropriately. Therefore, we performed placebo-controlled, double-blind, randomized study and extension study. One-hundred forty-three patients with active RA were randomized to receive placebo or infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance. Primary endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at 30 week. After the clinical trial, patients on placebo (Group 1) and patients on infliximab who showed ACR20 response (Group 2) were treated with infliximab through another 84 week for evaluation of safety. During clinical trial, patients in infliximab group showed higher ACR20 at week 30 than patients in placebo group (50.1% vs 30.6%, P=0.014). A total of 92 patients participated in the extension study. The maintenance rate of infliximab was 62.0% at 84 weeks of extension study. The overall rate of adverse events was not different between Group 1 and Group 2. In Korean patients with active RA despite methotrexate treatment, infliximab in combination with methotrexate is effective and the long-term treatment with infliximab is well tolerated.

Original languageEnglish
Pages (from-to)1716-1722
Number of pages7
JournalJournal of Korean Medical Science
Volume28
Issue number12
Publication statusPublished - 2013 Jan 1

Fingerprint

Methotrexate
Rheumatoid Arthritis
Clinical Trials
Placebos
Therapeutics
Rheumatology
Maintenance
Safety
Infliximab
Double-Blind Method

Keywords

  • Adverse event
  • Arthritis, rheumatoid
  • Efficacy
  • Extension study
  • Infliximab
  • Placebo-controlled clinical trial

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. / Kim, Jinhyun; Ryu, Heejung; Yoo, Dae Hyun; Park, Sung Hwan; Song, Gwan Gyu; Park, Won; Cho, Chul Soo; Song, Yeong Wook.

In: Journal of Korean Medical Science, Vol. 28, No. 12, 01.01.2013, p. 1716-1722.

Research output: Contribution to journalArticle

Kim, Jinhyun ; Ryu, Heejung ; Yoo, Dae Hyun ; Park, Sung Hwan ; Song, Gwan Gyu ; Park, Won ; Cho, Chul Soo ; Song, Yeong Wook. / A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. In: Journal of Korean Medical Science. 2013 ; Vol. 28, No. 12. pp. 1716-1722.
@article{10a180b61cb84b90a21127e15ecafb46,
title = "A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment",
abstract = "Currently, infliximab is given for disease control for active rheumatoid arthritis (RA) patients despite methotrexate treatment. However, the efficacy and safety of infliximab in Korean patients has not been assessed appropriately. Therefore, we performed placebo-controlled, double-blind, randomized study and extension study. One-hundred forty-three patients with active RA were randomized to receive placebo or infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance. Primary endpoint was American College of Rheumatology 20{\%} improvement criteria (ACR20) at 30 week. After the clinical trial, patients on placebo (Group 1) and patients on infliximab who showed ACR20 response (Group 2) were treated with infliximab through another 84 week for evaluation of safety. During clinical trial, patients in infliximab group showed higher ACR20 at week 30 than patients in placebo group (50.1{\%} vs 30.6{\%}, P=0.014). A total of 92 patients participated in the extension study. The maintenance rate of infliximab was 62.0{\%} at 84 weeks of extension study. The overall rate of adverse events was not different between Group 1 and Group 2. In Korean patients with active RA despite methotrexate treatment, infliximab in combination with methotrexate is effective and the long-term treatment with infliximab is well tolerated.",
keywords = "Adverse event, Arthritis, rheumatoid, Efficacy, Extension study, Infliximab, Placebo-controlled clinical trial",
author = "Jinhyun Kim and Heejung Ryu and Yoo, {Dae Hyun} and Park, {Sung Hwan} and Song, {Gwan Gyu} and Won Park and Cho, {Chul Soo} and Song, {Yeong Wook}",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "28",
pages = "1716--1722",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "12",

}

TY - JOUR

T1 - A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment

AU - Kim, Jinhyun

AU - Ryu, Heejung

AU - Yoo, Dae Hyun

AU - Park, Sung Hwan

AU - Song, Gwan Gyu

AU - Park, Won

AU - Cho, Chul Soo

AU - Song, Yeong Wook

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Currently, infliximab is given for disease control for active rheumatoid arthritis (RA) patients despite methotrexate treatment. However, the efficacy and safety of infliximab in Korean patients has not been assessed appropriately. Therefore, we performed placebo-controlled, double-blind, randomized study and extension study. One-hundred forty-three patients with active RA were randomized to receive placebo or infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance. Primary endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at 30 week. After the clinical trial, patients on placebo (Group 1) and patients on infliximab who showed ACR20 response (Group 2) were treated with infliximab through another 84 week for evaluation of safety. During clinical trial, patients in infliximab group showed higher ACR20 at week 30 than patients in placebo group (50.1% vs 30.6%, P=0.014). A total of 92 patients participated in the extension study. The maintenance rate of infliximab was 62.0% at 84 weeks of extension study. The overall rate of adverse events was not different between Group 1 and Group 2. In Korean patients with active RA despite methotrexate treatment, infliximab in combination with methotrexate is effective and the long-term treatment with infliximab is well tolerated.

AB - Currently, infliximab is given for disease control for active rheumatoid arthritis (RA) patients despite methotrexate treatment. However, the efficacy and safety of infliximab in Korean patients has not been assessed appropriately. Therefore, we performed placebo-controlled, double-blind, randomized study and extension study. One-hundred forty-three patients with active RA were randomized to receive placebo or infliximab 3 mg/kg intravenously at week 0, 2, 6, 14, and 22 with methotrexate maintenance. Primary endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at 30 week. After the clinical trial, patients on placebo (Group 1) and patients on infliximab who showed ACR20 response (Group 2) were treated with infliximab through another 84 week for evaluation of safety. During clinical trial, patients in infliximab group showed higher ACR20 at week 30 than patients in placebo group (50.1% vs 30.6%, P=0.014). A total of 92 patients participated in the extension study. The maintenance rate of infliximab was 62.0% at 84 weeks of extension study. The overall rate of adverse events was not different between Group 1 and Group 2. In Korean patients with active RA despite methotrexate treatment, infliximab in combination with methotrexate is effective and the long-term treatment with infliximab is well tolerated.

KW - Adverse event

KW - Arthritis, rheumatoid

KW - Efficacy

KW - Extension study

KW - Infliximab

KW - Placebo-controlled clinical trial

UR - http://www.scopus.com/inward/record.url?scp=84906527962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906527962&partnerID=8YFLogxK

M3 - Article

C2 - 24339699

AN - SCOPUS:84906527962

VL - 28

SP - 1716

EP - 1722

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 12

ER -